Posted by Michael Wonder on 14 Dec 2023
FDA grants priority review to Amgen's tarlatamab application for advanced small cell lung cancer
13 December 2023 - FDA target action date is 12 June 2024.
Amgen today announced that the US FDA has accepted and granted priority review for the Company's biologics license application for tarlatamab.
